Pain, PostoperativeLIA-PNB-TKANCT07744503
Comparing Local Anesthetic Injections to Nerve Blocks for Pain Control After Total Knee Replacement
A study testing Continuous Femoral and Sciatic Nerve Block (Ropivacaine) and Local Infiltration Analgesia (Ropivacaine, Ketorolac, Epinephrine) in people with Pain, Postoperative and Osteoarthritis, Knee, run by Christopher Male at 1 site in Austria.
Trial summary
Why are we doing this study? People who have knee replacement surgery often feel pain afterward. Doctors use different methods to control this pain. One method is an injection of numbing medicine directly into the knee during surgery, called local infiltration analgesia (LIA). Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Pain, Postoperative, Osteoarthritis, Knee, Arthroplasty, Replacement, Knee
- What is being tested?
- Continuous Femoral and Sciatic Nerve Block (Ropivacaine) and Local Infiltration Analgesia (Ropivacaine, Ketorolac, Epinephrine)
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 78 participants
- Where
- 1 siteAustria
- Study dates
- 1 Jun 2025to 31 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 to 90 years
- Primary or secondary knee osteoarthritis (gonarthrosis)
- Scheduled for elective primary total knee arthroplasty (cruciate-retaining implant)
- Ambulatory prior to surgery (able to walk unassisted)
- American Society of Anesthesiologists (ASA) physical status I-III
- Able to provide written informed consent
Who cannot join
- Post-traumatic knee arthropathy (trauma-related indication for surgery)
- Wheelchair use / inability to ambulate preoperatively
- ASA physical status IV or higher
- Lack of capacity to provide informed consent (e.g., legal guardianship/procurator required)
- Planned unicompartmental (hemi-) knee arthroplasty or revision surgery
- Known allergy or contraindication to the study medications (ropivacaine, ketorolac, or epinephrine)
Trial locations and contacts
1 site in 1 country.
Austria1 site
Elisabethinen Krankenhaus Klagenfurt
Klagenfurt, Carinthia, 9020
About this study
Official title: Comparison of Intraarticular Application of Local Anesthetics Versus Peripheral Regional Anesthesia in Patients With Total Arthroplasty of the Knee (K-TEP)
Why are we doing this study? People who have knee replacement surgery often feel pain afterward. Doctors use different methods to control this pain. One method is an injection of numbing medicine directly into the knee during surgery, called local infiltration analgesia (LIA). Another method uses a thin tube (catheter) placed near nerves in the leg to continuously deliver numbing medicine, called a nerve block. This study compares these two pain control methods after knee replacement surgery, to find out whether the injection method (LIA) works at least as well as the nerve block method for controlling pain.
Who can take part in this study? Adults aged 18 to 90 years who need a first-time (primary) knee replacement because of knee arthritis can take part. Participants must be able to walk before surgery, be in generally stable health, and be able to give informed consent. People with a knee injury (rather than arthritis), people who use a wheelchair, and people unable to give consent were not included.
What happens during this study? 78 participants were randomly assigned, like a coin flip, to receive either the injection into the knee (LIA) or the nerve block through a catheter for pain relief after surgery. Both groups also received the same standard pain medicines by mouth or vein as needed. Researchers measured pain levels using a 0-10 pain scale before surgery and at 24, 48, 72, and 96 hours afterward. They also measured knee movement (range of motion), how much extra pain medicine was needed, and how satisfied participants were with their pain control. The study took place at one hospital, the Elisabethinen Hospital in Klagenfurt, Austria, between June 2025 and January 2026.
Read the detailed description
This is a prospective, randomized, open-label, controlled non-inferiority trial conducted at a single center (Department of Orthopedics and Traumatology, Elisabethinen Krankenhaus Klagenfurt). The trial compares two established postoperative analgesic techniques for primary total knee arthroplasty (TKA): local infiltration analgesia (LIA) versus continuous peripheral regional anesthesia via femoral and sciatic nerve block. Both techniques are already in routine clinical use; this trial was designed to determine which approach provides superior or at least non-inferior pain control at this institution.
Hypothesis: The investigators hypothesized that LIA is not inferior to peripheral regional anesthesia with regard to postoperative pain control, measured on a 100 mm Visual Analogue Scale (VAS) 48 hours after surgery (VAS48). A non-inferiority margin of 10 mm was pre-specified, based on published minimal clinically important difference (MCID) estimates for postoperative pain on the VAS (approximately 8-40 mm across systematic reviews, with common MCID estimates near 10 mm). Non-inferiority is concluded if the upper limit of the one-sided 97.5% confidence interval of the mean difference (LIA minus nerve block) is below this margin.
Sample size: Assuming a between-group mean difference of 0 mm and a combined standard deviation of 15 mm (derived from comparable published TKA analgesia trials), a sample of 37 patients per group provides 80% power (one-sided alpha = 0.025) to demonstrate non-inferiority. Accounting for an anticipated 5% drop-out rate, 78 patients were enrolled in total.
Randomization and blinding: Patients were allocated 1:1 to the LIA or nerve block group using the institutional randomization tool of the Medical University of Graz. The trial is open-label; blinding of the anesthetic technique was not feasible given the distinct procedural nature of the two interventions.
In addition to the primary pain endpoint, the trial captures postoperative opioid consumption, range of motion (knee flexion, measured by goniometer) during early mobilization, and overall patient satisfaction with perioperative care and pain management, assessed using a standardized questionnaire (Anästhesiologischer Nachbefragungsbogen, ANP) at 24 and 96 hours postoperatively. Data were collected between June 2025 and January 2026. No external funding or commercial sponsorship was involved; statistical analysis was performed by the investigator.
- Being tested
- Continuous Femoral and Sciatic Nerve Block (Ropivacaine), Local Infiltration Analgesia (Ropivacaine, Ketorolac, Epinephrine)
- Keywords
- Total Knee Arthroplasty, Local Infiltration Analgesia, Peripheral Nerve Block, Femoral Nerve Block, Sciatic Nerve Block, Postoperative Pain Management, Visual Analogue Scale
- Medical subject headings
- Pain, Postoperative, Osteoarthritis, Knee
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous Femoral and Sciatic Nerve Block (Ropivacaine)Drug
Continuous peripheral regional anesthesia via ultrasound-guided femoral and sciatic nerve catheters, placed intraoperatively. Under general anesthesia, each catheter received an initial bolus of 15 mL mepivacaine 1.5% plus 10 mL ropivacaine 0.375%; under spinal anesthesia, an initial 15 mL normal saline (0.9%) test bolus confirmed catheter position, followed by 10 mL ropivacaine 0.375% once sensory block began to wear off. A continuous perineural infusion of ropivacaine 0.2% was then maintained via infusion pump for 48 hours postoperatively: 5 mL/h for the first 24 hours, reduced to 3 mL/h thereafter. Patients could additionally self-administer a 5 mL bolus every 30 minutes as needed. Catheters and the infusion pump were removed at 48 hours postoperatively.
Local Infiltration Analgesia (Ropivacaine, Ketorolac, Epinephrine)Drug
Periarticular local infiltration analgesia administered intraoperatively during total knee arthroplasty, comprising 150 mL ropivacaine 2 mg/mL (from a 200 mL preparation, first 50 mL discarded), 30 mg ketorolac (1 mL of 30 mg/mL solution), and 0.5 mg epinephrine hydrochloride (0.5 mL of 1 mg/mL solution). The combined solution was injected periarticularly by the operating surgeon as a single intraoperative dose during wound closure. Total ropivacaine dose did not exceed the maximum recommended dose of 300 mg. No repeat dosing was administered postoperatively for this arm.
| Study group | Role | What they receive |
|---|---|---|
| Local Infiltration Analgesia (LIA) | Experimental | Participants received intraoperative periarticular local infiltration analgesia consisting of 200 mL ropivacaine (2 mg/mL, first 50 mL discarded), 30 mg ketorolac, and 0.5 mg epinephrine, injected during total knee arthroplasty. All participants additionally received the standardized postoperative oral/intravenous analgesic regimen (diclofenac, hydromorphone, metamizole, paracetamol as needed). Receives: Drug: Local Infiltration Analgesia (Ropivacaine, Ketorolac, Epinephrine) |
| Peripheral Regional Anesthesia (Femoral and Sciatic Nerve Block) | Active comparator | Participants received continuous femoral and sciatic nerve block via perineural catheters. An initial local anesthetic bolus was followed by continuous ropivacaine 0.2% infusion for 48 hours postoperatively (5 mL/h for the first 24 hours, then reduced to 3 mL/h), with patient-controlled boluses available. The same standardized postoperative oral/intravenous analgesic regimen as the LIA group was administered. Receives: Drug: Continuous Femoral and Sciatic Nerve Block (Ropivacaine) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative Pain Intensity at 48 Hours (VAS Score)
Pain intensity measured with the Visual Analogue Scale (VAS), a 0-10 point scale where 0 indicates no pain and 10 indicates the worst pain imaginable (higher scores indicate worse pain), assessed at rest, at night, and during mobilization 48 hours after total knee arthroplasty. This measure was used to test non-inferiority of LIA versus peripheral regional (femoral/sciatic nerve block) anesthesia against a pre-specified non-inferiority margin.
Measured: 48 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Aug 2026
- Study start1 Jun 2025
- Primary completion31 Jan 2026
- Study completion31 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Pain, PostoperativeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants undergoing primary total knee arthroplasty were randomly allocated in a 1:1 ratio to one of two parallel treatment groups: local infiltration analgesia (LIA) or continuous peripheral regional anesthesia via femoral and sciatic nerve block. Each participant received only one of the two analgesic techniques throughout the perioperative and postoperative study period. Randomization was performed using the institutional randomization tool of the Medical University of Graz.
- Masking
- None (open label)
- Enrolment
- 78 participants (actual)
Sponsor and investigators
- Lead sponsor
- Christopher Male
- Sponsor type
- University, hospital or other
- Collaborators
- Elisabethinen Hospital
- Responsible party
- Sponsor-investigator, Christopher Male, Elisabethinen Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07744503
- Sponsor's protocol ID
- EK-S2025-11
- Acronym
- LIA-PNB-TKA
- Status last verified
- Jul 2026
- First submitted
- 30 Jul 2026
- Last updated
- 5 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data are not planned to be shared beyond the study team. In accordance with the data protection provisions of the study protocol, collected data are stored pseudonymized (no patient names) in a restricted-access institutional spreadsheet. No data-sharing infrastructure, repository, or governance process has been established for this single-center academic dissertation study.
Publications
Hu B, Lin T, Yan SG, Tong SL, Yu JH, Xu JJ, Ying YM. Local Infiltration Analgesia Versus Regional Blockade for Postoperative Analgesia in Total Knee Arthroplasty: A Meta-analysis of Randomized Controlled Trials. Pain Physician. 2016 May;19(4):205-14.
PubMed 27228509Kerr DR, Kohan L. Local infiltration analgesia: a technique for the control of acute postoperative pain following knee and hip surgery: a case study of 325 patients. Acta Orthop. 2008 Apr;79(2):174-83. doi: 10.1080/17453670710014950.
PubMed 18484242Myles PS, Myles DB, Galagher W, Boyd D, Chew C, MacDonald N, Dennis A. Measuring acute postoperative pain using the visual analog scale: the minimal clinically important difference and patient acceptable symptom state. Br J Anaesth. 2017 Mar 1;118(3):424-429. doi: 10.1093/bja/aew466.
PubMed 28186223Olsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, Hrobjartsson A. Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain. BMC Med. 2017 Feb 20;15(1):35. doi: 10.1186/s12916-016-0775-3.
PubMed 28215182
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Intraarticular Application of Local Anesthetics Versus Peripheral Regional Anesthesia in Patients With Total Arthroplasty of the Knee (K-TEP)
- ClinicalTrials.gov ID
- NCT07744503
- Acronym / sponsor ID
- LIA-PNB-TKA / EK-S2025-11
- Keywords
- Total Knee Arthroplasty, Local Infiltration Analgesia, Peripheral Nerve Block, Femoral Nerve Block, Sciatic Nerve Block, Postoperative Pain Management, Visual Analogue Scale
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 78 participants (actual)
- Lead sponsor
- Christopher MaleUniversity, hospital or other
- Collaborators
- Elisabethinen Hospital
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- 31 Jan 2026 (actual)
- Study completion
- 31 Jan 2026 (actual)
- First posted
- 4 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Why are we doing this study? People who have knee replacement surgery often feel pain afterward. Doctors use different methods to control this pain. One method is an injection of numbing medicine directly into the knee during surgery, called local infiltration analgesia (LIA). Another method uses a thin tube (catheter) placed near nerves in the leg to continuously deliver numbing medicine, called a nerve block. This study compares these two pain control methods after knee replacement surgery, to find out whether the injection method (LIA) works at least as well as the nerve block method for controlling pain.
Who can take part in this study? Adults aged 18 to 90 years who need a first-time (primary) knee replacement because of knee arthritis can take part. Participants must be able to walk before surgery, be in generally stable health, and be able to give informed consent. People with a knee injury (rather than arthritis), people who use a wheelchair, and people unable to give consent were not included.
What happens during this study? 78 participants were randomly assigned, like a coin flip, to receive either the injection into the knee (LIA) or the nerve block through a catheter for pain relief after surgery. Both groups also received the same standard pain medicines by mouth or vein as needed. Researchers measured pain levels using a 0-10 pain scale before surgery and at 24, 48, 72, and 96 hours afterward. They also measured knee movement (range of motion), how much extra pain medicine was needed, and how satisfied participants were with their pain control. The study took place at one hospital, the Elisabethinen Hospital in Klagenfurt, Austria, between June 2025 and January 2026.
Detailed description
This is a prospective, randomized, open-label, controlled non-inferiority trial conducted at a single center (Department of Orthopedics and Traumatology, Elisabethinen Krankenhaus Klagenfurt). The trial compares two established postoperative analgesic techniques for primary total knee arthroplasty (TKA): local infiltration analgesia (LIA) versus continuous peripheral regional anesthesia via femoral and sciatic nerve block. Both techniques are already in routine clinical use; this trial was designed to determine which approach provides superior or at least non-inferior pain control at this institution.
Hypothesis: The investigators hypothesized that LIA is not inferior to peripheral regional anesthesia with regard to postoperative pain control, measured on a 100 mm Visual Analogue Scale (VAS) 48 hours after surgery (VAS48). A non-inferiority margin of 10 mm was pre-specified, based on published minimal clinically important difference (MCID) estimates for postoperative pain on the VAS (approximately 8-40 mm across systematic reviews, with common MCID estimates near 10 mm). Non-inferiority is concluded if the upper limit of the one-sided 97.5% confidence interval of the mean difference (LIA minus nerve block) is below this margin.
Sample size: Assuming a between-group mean difference of 0 mm and a combined standard deviation of 15 mm (derived from comparable published TKA analgesia trials), a sample of 37 patients per group provides 80% power (one-sided alpha = 0.025) to demonstrate non-inferiority. Accounting for an anticipated 5% drop-out rate, 78 patients were enrolled in total.
Randomization and blinding: Patients were allocated 1:1 to the LIA or nerve block group using the institutional randomization tool of the Medical University of Graz. The trial is open-label; blinding of the anesthetic technique was not feasible given the distinct procedural nature of the two interventions.
In addition to the primary pain endpoint, the trial captures postoperative opioid consumption, range of motion (knee flexion, measured by goniometer) during early mobilization, and overall patient satisfaction with perioperative care and pain management, assessed using a standardized questionnaire (Anästhesiologischer Nachbefragungsbogen, ANP) at 24 and 96 hours postoperatively. Data were collected between June 2025 and January 2026. No external funding or commercial sponsorship was involved; statistical analysis was performed by the investigator.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants undergoing primary total knee arthroplasty were randomly allocated in a 1:1 ratio to one of two parallel treatment groups: local infiltration analgesia (LIA) or continuous peripheral regional anesthesia via femoral and sciatic nerve block. Each participant received only one of the two analgesic techniques throughout the perioperative and postoperative study period. Randomization was performed using the institutional randomization tool of the Medical University of Graz.
| Arm | Type | Receives |
|---|---|---|
| Local Infiltration Analgesia (LIA) | Experimental | Drug: Local Infiltration Analgesia (Ropivacaine, Ketorolac, Epinephrine)Participants received intraoperative periarticular local infiltration analgesia consisting of 200 mL ropivacaine (2 mg/mL, first 50 mL discarded), 30 mg ketorolac, and 0.5 mg epinephrine, injected during total knee arthroplasty. All participants additionally received the standardized postoperative oral/intravenous analgesic regimen (diclofenac, hydromorphone, metamizole, paracetamol as needed). |
| Peripheral Regional Anesthesia (Femoral and Sciatic Nerve Block) | Active comparator | Drug: Continuous Femoral and Sciatic Nerve Block (Ropivacaine)Participants received continuous femoral and sciatic nerve block via perineural catheters. An initial local anesthetic bolus was followed by continuous ropivacaine 0.2% infusion for 48 hours postoperatively (5 mL/h for the first 24 hours, then reduced to 3 mL/h), with patient-controlled boluses available. The same standardized postoperative oral/intravenous analgesic regimen as the LIA group was administered. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age 18 to 90 years
- Primary or secondary knee osteoarthritis (gonarthrosis)
- Scheduled for elective primary total knee arthroplasty (cruciate-retaining implant)
- Ambulatory prior to surgery (able to walk unassisted)
- American Society of Anesthesiologists (ASA) physical status I-III
Key exclusion criteria (6 listed)
- Post-traumatic knee arthropathy (trauma-related indication for surgery)
- Wheelchair use / inability to ambulate preoperatively
- ASA physical status IV or higher
- Lack of capacity to provide informed consent (e.g., legal guardianship/procurator required)
- Planned unicompartmental (hemi-) knee arthroplasty or revision surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous Femoral and Sciatic Nerve Block (Ropivacaine)Continuous peripheral regional anesthesia via ultrasound-guided femoral and sciatic nerve catheters, placed intraoperatively. Under general anesthesia, each catheter received an initial bolus of 15 mL mepivacaine 1.5% plus 10 mL ropivacaine 0.375%; under spinal anesthesia, an initial 15 mL normal saline (0.9%) test bolus confirmed catheter position, followed by 10 mL ropivacaine 0.375% once sensory block began to wear off. A continuous perineural infusion of ropivacaine 0.2% was then maintained via infusion pump for 48 hours postoperatively: 5 mL/h for the first 24 hours, reduced to 3 mL/h thereafter. Patients could additionally self-administer a 5 mL bolus every 30 minutes as needed. Catheters and the infusion pump were removed at 48 hours postoperatively. | Drug | Peripheral Regional Anesthesia (Femoral and Sciatic Nerve Block) |
| Local Infiltration Analgesia (Ropivacaine, Ketorolac, Epinephrine)Periarticular local infiltration analgesia administered intraoperatively during total knee arthroplasty, comprising 150 mL ropivacaine 2 mg/mL (from a 200 mL preparation, first 50 mL discarded), 30 mg ketorolac (1 mL of 30 mg/mL solution), and 0.5 mg epinephrine hydrochloride (0.5 mL of 1 mg/mL solution). The combined solution was injected periarticularly by the operating surgeon as a single intraoperative dose during wound closure. Total ropivacaine dose did not exceed the maximum recommended dose of 300 mg. No repeat dosing was administered postoperatively for this arm. | Drug | Local Infiltration Analgesia (LIA) |
Primary outcome
Postoperative Pain Intensity at 48 Hours (VAS Score)
Time frame: 48 hours postoperatively
Pain intensity measured with the Visual Analogue Scale (VAS), a 0-10 point scale where 0 indicates no pain and 10 indicates the worst pain imaginable (higher scores indicate worse pain), assessed at rest, at night, and during mobilization 48 hours after total knee arthroplasty. This measure was used to test non-inferiority of LIA versus peripheral regional (femoral/sciatic nerve block) anesthesia against a pre-specified non-inferiority margin.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2026.
- Results publication: PubMed 27228509Hu B, Lin T, Yan SG, Tong SL, Yu JH, Xu JJ, Ying YM. Local Infiltration Analgesia Versus Regional Blockade for Postoperative Analgesia in Total Knee Arthroplasty: A Meta-analysis of Randomized Controlled Trials. Pain Physician. 2016 May;19(4):205-14.
- Results publication: PubMed 18484242Kerr DR, Kohan L. Local infiltration analgesia: a technique for the control of acute postoperative pain following knee and hip surgery: a case study of 325 patients. Acta Orthop. 2008 Apr;79(2):174-83. doi: 10.1080/17453670710014950.
- Results publication: PubMed 28186223Myles PS, Myles DB, Galagher W, Boyd D, Chew C, MacDonald N, Dennis A. Measuring acute postoperative pain using the visual analog scale: the minimal clinically important difference and patient acceptable symptom state. Br J Anaesth. 2017 Mar 1;118(3):424-429. doi: 10.1093/bja/aew466.
- Results publication: PubMed 28215182Olsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, Hrobjartsson A. Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain. BMC Med. 2017 Feb 20;15(1):35. doi: 10.1186/s12916-016-0775-3.
- Individual participant dataSharing planned: No. Individual participant data are not planned to be shared beyond the study team. In accordance with the data protection provisions of the study protocol, collected data are stored pseudonymized (no patient names) in a restricted-access institutional spreadsheet. No data-sharing infrastructure, repository, or governance process has been established for this single-center academic dissertation study.
Related trials for Pain, Postoperative
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Active, not recruitingPhase 4
Effect of Dexmedetomidine on Postoperative Pain in Spinal Anesthesia for Cesarean Section at Assuit University Hospital
Cesarean Section
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Continuous Femoral and Sciatic Nerve Block (Ropivacaine) and Local Infiltration Analgesia (Ropivacaine, Ketorolac, Epinephrine) in people with Pain, Postoperative and Osteoarthritis, Knee, run by Christopher Male at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative Pain Intensity at 48 Hours (VAS Score) (time frame: 48 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07744503, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2026.